不同含铂治疗方案在晚期非小细胞肺癌患者中的应用效果.docVIP

不同含铂治疗方案在晚期非小细胞肺癌患者中的应用效果 　　[摘要] 目的 比?^不同含铂的化疗方案对晚期非小细胞肺癌（NSCLC）的疗效及安全性。 方法 选取2009年1月～2013年1月首都医科大学附属北京潞河医院初治的164例晚期NSCLC患者为研究对象，164例患者根据一线化疗方案分为紫杉醇组（紫杉醇联合铂类，n=78）、吉西他滨组（吉西他滨联合铂类，n=49）和多西他赛组（多西他赛联合铂类，n=37）。比较三组的疗效及不良反应，并用Kaplan-Meier法方法评估生存状况。 结果 紫杉醇组、吉西他滨组和多西他赛组化疗后达到客观有效的比例分别为43.6%、46.9%、37.8%，达到疾病控制的比例分为87.2%、83.7%及81.1%，差异无统计学意义（均P 0.05）。不良反应主要是血液学毒性，其次是脱发、胃肠道毒性、神经毒性、肾脏毒性、心脏毒性和肝脏毒性，紫杉醇组的神经毒性的发生率明显高于另外两组（P 　　[关键词] 非小细胞肺癌；化疗；不良反应 　　[中图分类号] R734.2 [文献标识码] A [文章编号] 1673-7210（2016）12（b）-0102-04 　　Effect of different platinum-based combination chemotherapies for patients with advanced non-small-cell lung cancer 　　KONG Bin 　　Department of Oncology，Beijing Luhe Hospital， Capital Medical University， Beijing 101149， China 　　[Abstract] Objective To compare the efficacies and safety of different platinum-based combination chemotherapies for patients with advanced non-small-cell lung cancer （NSCLC）. Methods 164 patients initially treated in Beijing Luhe Hospital， Capital Medical University from January 2009 to January 2013 were enrolled for study. According to the first-line chemotherapy regiments， 164 cases were divided into Paclitaxel group （Paclitaxel combined with platinum， n=78）， Gemcitabine group （Gemcitabine combined with platinum， n=49） and Docetaxel group （docetaxel combined with platinum， n=37）. The efficacies and adverse reactions were compared among three groups， and Kaplan-Meier method was used to evaluate the survival situation. Results The objective response rate （ORR） of Paclitaxel group， Gemcitabine group and Docetaxel group were 43.6%， 46.9% and 37.8%， and the disease control rate （DCR） of three groups were 87.2%， 83.7% and 81.1%. There were no significant differences in ORR an DCR among three groups （all P 0.05）. Adverse reactions were mainly hematological toxicity， followed by alopecia， gastrointestinal toxicity， neurotoxicity， renal toxicity， cardiac toxicity and liver toxicity. The incidence of neurotoxicity of Paclitaxel group was significantl